Q-omics provides the consensus-scored CSN3 profile across patient tissues and cancer cell-line models. CSN3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CSN3 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, CSN3 RNA expression shows 6,657 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, BRCA, and STAD as cancer lineages where CSN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSN3 survival associations across molecular data types. CSN3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSN3 RNA expression–survival associations across cancer types. High CSN3 expression shows unfavorable associations in UCEC and MESO, but favorable associations in STAD, BRCA, LUAD and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CSN3 RNA expression.
This table summarizes CSN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CSN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSN3 shows lower tumor expression in BRCA, HNSC and THCA and higher tumor expression in KIRC, LUSC and ESCA. The BRCA box plot shows higher CSN3 RNA expression in normal versus tumor tissue (log2 FC = −1.491, t-test p < 0.001).
This table shows molecular features associated with CSN3 in patient tissues and cancer cell lines. In patient samples, CSN3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CSN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
